Stephanie Davis
Stock Analyst at Barclays
(1.06)
# 2,699
Out of 4,412 analysts
81
Total ratings
31.03%
Success rate
-18.49%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LH Laboratory Corporation of America Holdings | Maintains: Equal-Weight | $234 → $213 | $198.40 | +7.36% | 2 | Apr 26, 2024 | |
| DGX Quest Diagnostics | Maintains: Equal-Weight | $138 → $144 | $134.26 | +7.25% | 1 | Apr 25, 2024 | |
| WW WW International | Maintains: Underweight | $8 → $1.5 | $1.75 | -14.29% | 1 | Mar 1, 2024 | |
| RCM R1 RCM | Downgrades: Equal-Weight | $14 | $11.90 | +17.65% | 4 | Feb 28, 2024 | |
| TALK Talkspace | Maintains: Equal-Weight | $2.5 → $3 | $3.12 | -3.85% | 6 | Feb 23, 2024 | |
| OPRX OptimizeRx | Initiates: Equal-Weight | $15 | $10.12 | +48.22% | 1 | Jan 3, 2024 | |
| PHR Phreesia | Initiates: Overweight | $29 | $20.61 | +40.71% | 11 | Jan 3, 2024 | |
| MDRX Veradigm | Initiates: Equal-Weight | $11 | $7.96 | +38.19% | 8 | Jan 3, 2024 | |
| COR Cencora | Initiates: Overweight | $242 | $240.88 | +0.46% | 1 | Jan 3, 2024 | |
| CAH Cardinal Health | Initiates: Overweight | $117 | $103.21 | +13.36% | 1 | Jan 3, 2024 | |
| TDOC Teladoc Health | Upgrades: Outperform | $34 | $13.01 | +161.34% | 8 | Feb 23, 2023 | |
| PINC Premier | Maintains: Outperform | $46 → $42 | $20.96 | +100.38% | 2 | Feb 8, 2023 | |
| PGNY Progyny | Downgrades: Market Perform | $59 → $34 | $32.04 | +6.12% | 3 | Jan 5, 2023 | |
| VEEV Veeva Systems | Maintains: Outperform | $242 → $233 | $200.91 | +15.97% | 8 | Dec 2, 2022 | |
| HCAT Health Catalyst | Maintains: Outperform | $20 → $17 | $6.03 | +181.92% | 8 | Nov 9, 2022 | |
| ACCD Accolade | Maintains: Market Perform | $8 → $13 | $7.89 | +64.77% | 7 | Oct 7, 2022 | |
| GDRX GoodRx Holdings | Maintains: Market Perform | $8 → $11 | $7.19 | +52.99% | 5 | Aug 9, 2022 | |
| HQY HealthEquity | Maintains: Outperform | $67 → $76 | $80.26 | -5.31% | 2 | Jun 7, 2022 | |
| DOCS Doximity | Maintains: Outperform | $72 → $67 | $23.82 | +181.28% | 2 | May 18, 2022 |
Laboratory Corporation of America Holdings
Apr 26, 2024
Maintains: Equal-Weight
Price Target: $234 → $213
Current: $198.40
Upside: +7.36%
Quest Diagnostics
Apr 25, 2024
Maintains: Equal-Weight
Price Target: $138 → $144
Current: $134.26
Upside: +7.25%
WW International
Mar 1, 2024
Maintains: Underweight
Price Target: $8 → $1.5
Current: $1.75
Upside: -14.29%
R1 RCM
Feb 28, 2024
Downgrades: Equal-Weight
Price Target: $14
Current: $11.90
Upside: +17.65%
Talkspace
Feb 23, 2024
Maintains: Equal-Weight
Price Target: $2.5 → $3
Current: $3.12
Upside: -3.85%
OptimizeRx
Jan 3, 2024
Initiates: Equal-Weight
Price Target: $15
Current: $10.12
Upside: +48.22%
Phreesia
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $20.61
Upside: +40.71%
Veradigm
Jan 3, 2024
Initiates: Equal-Weight
Price Target: $11
Current: $7.96
Upside: +38.19%
Cencora
Jan 3, 2024
Initiates: Overweight
Price Target: $242
Current: $240.88
Upside: +0.46%
Cardinal Health
Jan 3, 2024
Initiates: Overweight
Price Target: $117
Current: $103.21
Upside: +13.36%
Teladoc Health
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $13.01
Upside: +161.34%
Premier
Feb 8, 2023
Maintains: Outperform
Price Target: $46 → $42
Current: $20.96
Upside: +100.38%
Progyny
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $32.04
Upside: +6.12%
Veeva Systems
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $200.91
Upside: +15.97%
Health Catalyst
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $6.03
Upside: +181.92%
Accolade
Oct 7, 2022
Maintains: Market Perform
Price Target: $8 → $13
Current: $7.89
Upside: +64.77%
GoodRx Holdings
Aug 9, 2022
Maintains: Market Perform
Price Target: $8 → $11
Current: $7.19
Upside: +52.99%
HealthEquity
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $80.26
Upside: -5.31%
Doximity
May 18, 2022
Maintains: Outperform
Price Target: $72 → $67
Current: $23.82
Upside: +181.28%